These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. Kindelberger DW; Lee Y; Miron A; Hirsch MS; Feltmate C; Medeiros F; Callahan MJ; Garner EO; Gordon RW; Birch C; Berkowitz RS; Muto MG; Crum CP Am J Surg Pathol; 2007 Feb; 31(2):161-9. PubMed ID: 17255760 [TBL] [Abstract][Full Text] [Related]
3. [Preliminary study on the relationship between tubal intraepithelial carcinoma of the fimbria and pelvic high-grade serous carcinoma]. Liang Y; Chen XD; Lü BJ; Zhou CY; Zhang XF; Shi HY Zhonghua Fu Chan Ke Za Zhi; 2011 Oct; 46(10):724-8. PubMed ID: 22321343 [TBL] [Abstract][Full Text] [Related]
4. [Morphological features of the fimbria of the fallopian tube in pelvic serous adenocarcinoma]. Guo DH; Pang SJ; Shen Y; Li Y Zhonghua Zhong Liu Za Zhi; 2011 Apr; 33(4):287-90. PubMed ID: 21575501 [TBL] [Abstract][Full Text] [Related]
5. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas]. Shao HL; Shen DH; Xue WC; Li Y; Yu YZ Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760 [TBL] [Abstract][Full Text] [Related]
6. TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma--evidence supporting the clonal relationship of the two lesions. Kuhn E; Kurman RJ; Vang R; Sehdev AS; Han G; Soslow R; Wang TL; Shih IeM J Pathol; 2012 Feb; 226(3):421-6. PubMed ID: 21990067 [TBL] [Abstract][Full Text] [Related]
7. Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas. Hsu CY; Bristow R; Cha MS; Wang BG; Ho CL; Kurman RJ; Wang TL; Shih IeM Clin Cancer Res; 2004 Oct; 10(19):6432-6. PubMed ID: 15475429 [TBL] [Abstract][Full Text] [Related]
8. Are all pelvic (nonuterine) serous carcinomas of tubal origin? Przybycin CG; Kurman RJ; Ronnett BM; Shih IeM; Vang R Am J Surg Pathol; 2010 Oct; 34(10):1407-16. PubMed ID: 20861711 [TBL] [Abstract][Full Text] [Related]
9. Identical TP53 mutations in pelvic carcinosarcomas and associated serous tubal intraepithelial carcinomas provide evidence of their clonal relationship. Ardighieri L; Mori L; Conzadori S; Bugatti M; Falchetti M; Donzelli CM; Ravaggi A; Odicino FE; Facchetti F Virchows Arch; 2016 Jul; 469(1):61-9. PubMed ID: 27059324 [TBL] [Abstract][Full Text] [Related]
10. The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas. Köbel M; Reuss A; du Bois A; Kommoss S; Kommoss F; Gao D; Kalloger SE; Huntsman DG; Gilks CB J Pathol; 2010 Oct; 222(2):191-8. PubMed ID: 20629008 [TBL] [Abstract][Full Text] [Related]
11. Na K; Sung JY; Kim HS Anticancer Res; 2017 Dec; 37(12):6697-6703. PubMed ID: 29187446 [TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical overexpression of p16 and p53 in uterine serous carcinoma and ovarian high-grade serous carcinoma. Chiesa-Vottero AG; Malpica A; Deavers MT; Broaddus R; Nuovo GJ; Silva EG Int J Gynecol Pathol; 2007 Jul; 26(3):328-33. PubMed ID: 17581420 [TBL] [Abstract][Full Text] [Related]
13. Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases. Yemelyanova A; Ji H; Shih IeM; Wang TL; Wu LS; Ronnett BM Am J Surg Pathol; 2009 Oct; 33(10):1504-14. PubMed ID: 19623034 [TBL] [Abstract][Full Text] [Related]
14. Subdividing ovarian and peritoneal serous carcinoma into moderately differentiated and poorly differentiated does not have biologic validity based on molecular genetic and in vitro drug resistance data. Vang R; Shih IeM; Salani R; Sugar E; Ayhan A; Kurman RJ Am J Surg Pathol; 2008 Nov; 32(11):1667-74. PubMed ID: 18769340 [TBL] [Abstract][Full Text] [Related]
15. Expression of p53, p21WAF1/CIP1, p16INK4A and Ki-67 proteins in serous ovarian tumors. Buchynska LG; Nesina IP; Yurchenko NP; Bilyk OO; Grinkevych VN; Svintitsky VS Exp Oncol; 2007 Mar; 29(1):49-53. PubMed ID: 17431389 [TBL] [Abstract][Full Text] [Related]
16. The emerging role of the distal Fallopian tube and p53 in pelvic serous carcinogenesis. Herrington CS; McCluggage WG J Pathol; 2010 Jan; 220(1):5-6. PubMed ID: 19882674 [TBL] [Abstract][Full Text] [Related]
17. Second primary or recurrence? Comparative patterns of p53 and K-ras mutations suggest that serous borderline ovarian tumors and subsequent serous carcinomas are unrelated tumors. Ortiz BH; Ailawadi M; Colitti C; Muto MG; Deavers M; Silva EG; Berkowitz RS; Mok SC; Gershenson DM Cancer Res; 2001 Oct; 61(19):7264-7. PubMed ID: 11585764 [TBL] [Abstract][Full Text] [Related]
18. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Bonome T; Lee JY; Park DC; Radonovich M; Pise-Masison C; Brady J; Gardner GJ; Hao K; Wong WH; Barrett JC; Lu KH; Sood AK; Gershenson DM; Mok SC; Birrer MJ Cancer Res; 2005 Nov; 65(22):10602-12. PubMed ID: 16288054 [TBL] [Abstract][Full Text] [Related]